
Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC
Keywords: ARV; antiretroviral; FDA; Food and Drug Administration; ENF; Enfuvirtide; MVC; Maraviroc; VCV; Vicriviroc; HR1; first heptad repeat region; HR2; second heptad repeat region; pol; polimerase; env; envelope; CRF; circulating recombinant form; URF; unique re